☆ 4.7 Meeting Abstract

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

BLOOD (2016)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.3167.3167

Keywords

-

Categories

Hematology

Funding

  1. Onconova Therapeutics, Inc.
  2. Karyopharm
  3. Pfizer
  4. Sunesis
  5. Kiromic
  6. BMS
  7. Agios
  8. Celgene
  9. Abbvie
  10. Daiichi Sankyo
  11. Reata Pharmaceuticals
  12. Genentech
  13. Stemline
  14. Eli Lilly
  15. Cellectis
  16. Calithera
  17. Teva
  18. Patents Royalties
  19. Novartis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.